Miljenko,
No apologies needed; that was a joke intended to compliment your knowledge and experience in this area. I can understand why you wouldn't want to make it easy for us to follow your trades.
It simply points out that most of us can't do as deep DD as you. Those of us in that category are pleased to see you show up at all!
I'm starting to agree with you about clueless analysts on CCs. Not one question about the issue of blood infections with CA4P. Important, as you point out, because the risk/reward for patients in this population for this drug looked acceptable with just the cardiac and vascular issues. But throw in the systemic attacking of blood infections, and it's a different picture.
Interesting, however, that this issue never showed up in the SI OXGN thread, though you apparently came across it in late May. There are few Yahoo! boards worth wading through, do we all have to do it? When one of us finds something of this import, couldn't it be shared to save the rest the trouble? I thought that's what these boards were for. If I had any problem here it was my own in not finding it by myself. But it would have been nice to be pointed at this earlier, is all.
Raf inhibitor: tough target? Gotta bone up on the reasons . . .
Cheers, and Thanks for Everything, Tuck
PS: Does your cat really smoke? Not using the cat in NSCLC studies are you? It's a hilarious picture, whatever the case. |
